ARL Designs LLC United States

Single cell research has been identified as essential to the discovery of effective new drugs. Our team at ARL Designs has developed the Nano-Droplet Array Plate, an entirely new approach that satisfies this unmet need for isolating and studying individual cells over time.  Key to the proven success of this technology is our unique surface structure which causes nano-droplets to self-align and entrap individual cells at precise locations in large, high-density arrays.  Low fabrication costs will help drive this technology into the rapidly expanding market for 3D cell culture.

  

Dr Elizabeth (Beth) Kujan
Dr Elizabeth (Beth) Kujan
VP Market Development 

Arthur Andrew Medical United States

Founded by current CEO Justin Andrew Marsh. Mr. Marsh, a former microchip engineer and automation control contractor for companies such as Motorola, Intel and Medtronic, developed the company as a majority investor. The company originally specialized in the importation of enzymes and other raw materials.  As a majority of today’s current pharmaceuticals are designed to mimic enzymes, the company strives to develop and discover new medicines through enzyme research and development.


In 2003 Justin Andrew Marsh bought out his minority investors and Arthur Andrew Medical was formed. With the collaboration of well-known enzymologists and best-in-class materials, Arthur Andrew Medical began to create finished products under its own brand-name. In 2003, Neprinol, the world’s most potent systemic enzyme was born. Arthur Andrew's mission is to be the leader in the development of systemic enzyme products in the enzyme-pharma and supplement industry. While other companies develop products based on market trends and fads, Arthur Andrew Medical only adopts products with ingredients that have extensive clinical research for safety and efficacy.

Mr Aaron Gillam
President 

Aubourg Consulting, LLC United States

Mr Yves Francois Aubourg
Principal Owner 

Autism Speaks United States

This year marks 10 years of progress since Autism Speaks first opened its doors in 2005. As we move into our 11th year our goal is to significantly enhance autism services in every  community and push to get the groundbreaking ABLE Act , now the law of the land, implemented in all 50 states. Our dedicated field teams will be the ones heading this effort.

Thanks to the passion and generosity of our community, Autism Speaks has helped advance our understanding and treatment of autism in ways almost unimaginable ten years ago. 

Dr Daniel Smith
Vice President, Innovative Technologies 

Axenis France

YOUR INNOVATIVE SOLUTION:

AXENIS business model is based on the following three ideas :

-Central focus on humanized mouse models and their applications;

-Feed the flow of in-licensed new models and innovations in order to generate the richest possible catalogue of humanized models and pre-clinical studies and accumulate latest models and

related knowledge

-Offer pre-clinical studies to the biopharma industry.

 

WHICH PROBLEM ARE YOU SOLVING?

-Human immuno-profiling for drug discovery and validation;

-Searching for and validating predictive biomarkers of disease progression or resolution (infection, autoimmunity, tumor control…);development/Validation of vaccine, biologicals, small molecules, adjuvants and mAb treatments;

 

TARGET PARTNERS:

Partners/Licensing of immunodeficient mice :

Ø  PDX models/Sell

Ø  US/Asia/India/Europa

Ø  Co-development of new combine models (Liver/Tumor/Muscle..)

 

KEY VALUE PROPOSITION:

It will specialize in bringing the newest validated models to its clients and exploiting these models through in-house experimental studies. The vision of the founders is to make AXENIS a world-wide leading service company in humanized models.

Website:
www.axenis.fr
Dr Erwan Corcuff
CEO 

AzurRx BioPharma United States

AzurRx BioPharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. AzurRx BioPharma, Inc. is a recently founded private biotechnology company formed to focus on the development of the early stage pharmaceutical assets of ProteaBio Europe. The company is headquartered in New York, NY, with scientific operations based in Langlade, France.

Mr Thijs Spoor
CEO 

AzurRx BioPharma, Inc. United States

AzurRx BioPharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. AzurRx BioPharma, Inc. is a recently founded private biotechnology company formed to focus on the development of the early stage pharmaceutical assets of ProteaBio Europe. The company is headquartered in New York, NY, with scientific operations based in Langlade, France.

Mr Martin Krusin
Vice President, Business Development 

B CELL DESIGN France

B Cell Design promotes a new approach of mucosal immunotherapies. The innovation is based on a technology platform to generate a large number of drug and vaccine candidates in infectious diseases and oncology.

The preferential tropism of class A isotype for mucosal compartments is the key in treatment of infectious diseases and mucosal cancers (gut, lung) strategies.  Its high resistance (under its secretory form) through the entire digestive tracts, allow an oral administration of anti-cancer immunotherapy. B CELL DESIGN develops a new concept of therapeutic IgA and secretory IgA for anti-colorectal cancer therapy and medical imaging of early-stage metastasis. To target AIDS, B Cell Design develops an alternative vaccine approach for a mucosal induction of a neutralizing response, at the gate of entrance of the virus.

Based on an innovative platform of humanized transgenic mice models, B CELL DESIGN offers a complete panel of specific monoclonal antibodies, hIgG1, hIgA1, hIgA2, SIgA1, hIgM and hIgE. The main issue in the diagnostic industry is to solve the problem of supply in specific human sera, as positive controls and calibrators for their diagnostic kits. Plus, for some diseases, patients developed a combined immune response, requiring testing various isotypes. B CELL DESIGN offers secure solutions to overcome supplying restraints. Working with monoclonal antibodies offers a perfect reproducibility of antibodies affinity, allows keeping quality track of all components of the kit, and ensures a complete safety for users because of a non-human cellular manufacturing system.

 

OBJECTIVES :

B CELL DESIGN is seeking for partners to pursue the development of our drug candidates and to  initiate new projects based on our technological platform.

Armelle CUVILLIER
Chairman, C.S.O 

Bancroft United States

Bancroft is a leading provider of programs and supports for children and adults with autism, intellectual or developmental disabilities, and those in need of neurological rehabilitation. Our services include special education, vocational training and supported employment, structured day programs, campus and community living programs, short-term behavioral stabilization services for children, in-home and outpatient services.

A private, nonprofit organization, Bancroft was founded in Haddonfield, N.J., in 1883. Over the years, we have grown to become the fifth-largest private employer in Camden County. We currently serve more than 1,500 children and adults annually in settings throughout Camden, Burlington, Gloucester, Ocean, Middlesex and Salem counties in New Jersey, and in southeastern Pennsylvania and northern Delaware.

For 130 years, Bancroft has been making a difference in the lives of many. The organization is well known for helping people with disabilities achieve fulfilling lives while improving their function, activity and participation in society. Bancroft’s reputation for excellence is based on our commitment to providing a spectrum of individualized services, treating each person with respect and dignity, and providing services in an encouraging and supportive environment.

Adam Berr
‎Director Business Transformation 
Lauren Troy
Clinical Director 

BBRC-Aminogram France

BBRC-Aminogram BBRC- Aminogram is the French & European specialist in mobile and connected Bio- Impedance Analysis devices. Industry sectors E health Therapeutics Area Cardiology / Vascular Diseases
Endocrinology
Gastroenterology / Hepatology
Immunology
Infectious Diseases - Vaccines
Ivd / Diagnostics
Nutrition and Weight Loss
Oncology
Pulmonary/Respiratory Diseases
Rare Disease
Rheumatology
Your innovative solution

As a part of our advanced concept and system combining mobile hardware with sensor, smarts of software engines capabilities and personalized dashboard; our exclusive & patented BIA measurement & analysis offers a direct valuation of body composition, hydration and nutrition status at one glance.

Which problem are you solving ?

Our unique 

Target market segments

Health/weight management/Sport/Seniors/

Key value proposition

Connected Device & cloud based engine & storage technology/ The only one in this range of product to deliver instantly full body composition analysis/ Accurate & reliable / Highly personalizable and flexible

Dominique Grillet
Manager directeur